Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$102.97 USD

102.97
668,578

-0.19 (-0.18%)

Updated Sep 24, 2025 04:00 PM ET

After-Market: $102.99 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (104 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

HealthEquity (HQY) Surpasses Q2 Earnings Estimates, FY24 View Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the second quarter of fiscal 2024.

Zacks Equity Research

Why You Should Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Zacks Equity Research

Here's Why You Should Retain PacBio (PACB) Stock for Now

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Abbott's (ABT) New Positive Data Favors OCT in Stent Implantation

by Zacks Equity Research

Abbott's (ABT) latest late-breaking data reflects OCT's potential to improve clinical practice related to stent placement.

Zacks Equity Research

Masimo's (MASI) Inks Agreement to Improve Patient Outcomes

by Zacks Equity Research

Masimo's (MASI) latest deal with FMOLHS is expected to enhance patient safety and improve patient outcomes.

Zacks Equity Research

Phibro (PAHC) Q4 Earnings Miss Estimates, Gross Margin Falls

by Zacks Equity Research

Robust performance across the Animal Health segment is encouraging for Phirbo (PAHC).

Zacks Equity Research

Veeva Systems (VEEV) Beats on Q2 Earnings, Revises FY24 Outlook

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both segments.

Zacks Equity Research

Catalent (CTLT) Preliminary Q4 Revenues Dampened by Lower Sales

by Zacks Equity Research

Catalent (CTLT) records lower revenues in Biologics segment in its fourth-quarter fiscal 2023, resulting in overall soft preliminary performance.

Zacks Equity Research

Medtronic's (MDT) Inceptiv Spinal Cord Stimulator Gets CE Mark

by Zacks Equity Research

Medtronic's (MDT) Inceptiv SCS System is the first Medtronic SCS device to offer a closed-loop feature that senses each person's unique biological signals.

Zacks Equity Research

BrainsWay (BWAY) Expands Foothold in Taiwan With Deep TMS

by Zacks Equity Research

The collaboration between BrainsWay (BWAY) and Unison Healthcare Group signifies a coordinated effort to enhance access and awareness of Deep TMS in Taiwan.

Zacks Equity Research

LabCorp (LH) Suffers From Lower COVID Test Sales, Macro Woes

by Zacks Equity Research

Labcorp's (LH) Early Development Research Laboratories business continues to be constrained by NHP-related supply-chain issues.

Zacks Equity Research

Charles River (CRL) Collaborates With Fondazione Telethon

by Zacks Equity Research

Charles River (CRL) is excited about Fondazione Telethon's collaboration to produce HQ plasmid DNA for the lentivirus used in ex vivo gene therapy developed by Fondazione Telethon.

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) on the expanded global installed base of more than 3,250 Panthers instruments, representing the catalyst for sustained growth.

Zacks Equity Research

Veeva Systems (VEEV) to Support Civica Rx Quality Control

by Zacks Equity Research

Veeva Systems' (VEEV) Vault LIMS will streamline internal testing and manufacturing while promoting lead time adherence.

Zacks Equity Research

Thermo Fisher (TMO) Launches New Chromosomal Microarray

by Zacks Equity Research

Thermo Fisher's (TMO) CytoScan HD Accel array can save labs weeks or even months by accelerating the time it takes to get findings from cytogenetic research.

Zacks Equity Research

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Up (Revised)

by Zacks Equity Research

Strength across businesses and geographies, driven by execution, innovation, and improved underlying fundamentals contributes to Medtronic (MDT) Q1 revenues.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) successful integration of the recently-acquired business and raised guidance.

Zacks Equity Research

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Strength across businesses and geographies, driven by execution, innovation and improved underlying fundamentals, contributes to Medtronic's (MDT) Q1 revenues.

Zacks Equity Research

Here's Why You Should Invest in Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN), led by Invisalign portfolio expansion and raised guidance.

Zacks Equity Research

3 Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Zacks Equity Research

Here's Why You Should Invest in Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are upbeat about Penumbra (PEN) on Strong uptake following the launch of Lightning Flash, which accelerated top-line growth.

Zacks Equity Research

What's in the Cards for Medtronic (MDT) in Q1 Earnings?

by Zacks Equity Research

Strength across all businesses is likely to drive Medtronic's (MDT) first-quarter performance.

Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

The Zacks Analyst Blog Highlights Abcam, Integer Holdings and RxSight

by Zacks Equity Research

Abcam, Integer Holdings and RxSight are part of the Zacks top Analyst Blog.